277 related articles for article (PubMed ID: 23975430)
1. Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer.
Roy SS; Gonugunta VK; Bandyopadhyay A; Rao MK; Goodall GJ; Sun LZ; Tekmal RR; Vadlamudi RK
Oncogene; 2014 Jul; 33(28):3707-16. PubMed ID: 23975430
[TBL] [Abstract][Full Text] [Related]
2. Significance of PELP1 in ER-negative breast cancer metastasis.
Roy S; Chakravarty D; Cortez V; De Mukhopadhyay K; Bandyopadhyay A; Ahn JM; Raj GV; Tekmal RR; Sun L; Vadlamudi RK
Mol Cancer Res; 2012 Jan; 10(1):25-33. PubMed ID: 22086908
[TBL] [Abstract][Full Text] [Related]
3. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.
Cortez V; Mann M; Tekmal S; Suzuki T; Miyata N; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Vadlamudi RK
Breast Cancer Res; 2012 Jul; 14(4):R108. PubMed ID: 22812534
[TBL] [Abstract][Full Text] [Related]
4. PELP1 oncogenic functions involve CARM1 regulation.
Mann M; Cortez V; Vadlamudi R
Carcinogenesis; 2013 Jul; 34(7):1468-75. PubMed ID: 23486015
[TBL] [Abstract][Full Text] [Related]
5. PELP1 oncogenic functions involve alternative splicing via PRMT6.
Mann M; Zou Y; Chen Y; Brann D; Vadlamudi R
Mol Oncol; 2014 Mar; 8(2):389-400. PubMed ID: 24447537
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.
Chakravarty D; Roy SS; Babu CR; Dandamudi R; Curiel TJ; Vivas-Mejia P; Lopez-Berestein G; Sood AK; Vadlamudi RK
Clin Cancer Res; 2011 Apr; 17(8):2250-9. PubMed ID: 21421858
[TBL] [Abstract][Full Text] [Related]
7. PELP1 is a novel oncogene in gastric tumorigenesis and negatively regulated by miR-15 family microRNAs.
Ma C; Miao C; Wang C; Song F; Luo M
Cancer Biomark; 2019; 26(1):1-9. PubMed ID: 31322541
[TBL] [Abstract][Full Text] [Related]
8. Restin suppressed epithelial-mesenchymal transition and tumor metastasis in breast cancer cells through upregulating mir-200a/b expression via association with p73.
Lu Z; Jiao D; Qiao J; Yang S; Yan M; Cui S; Liu Z
Mol Cancer; 2015 May; 14():102. PubMed ID: 25972084
[TBL] [Abstract][Full Text] [Related]
9. Cancer Stem Cell Phenotypes in ER
Truong TH; Hu H; Temiz NA; Hagen KM; Girard BJ; Brady NJ; Schwertfeger KL; Lange CA; Ostrander JH
Mol Cancer Res; 2018 Apr; 16(4):707-719. PubMed ID: 29348189
[TBL] [Abstract][Full Text] [Related]
10. Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer.
Lee JY; Park MK; Park JH; Lee HJ; Shin DH; Kang Y; Lee CH; Kong G
Oncogene; 2014 Mar; 33(10):1325-35. PubMed ID: 23474752
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.
Gonugunta VK; Sareddy GR; Krishnan SR; Cortez V; Roy SS; Tekmal RR; Vadlamudi RK
Mol Cancer Ther; 2014 Jun; 13(6):1578-88. PubMed ID: 24688046
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor.
Rajhans R; Nair S; Holden AH; Kumar R; Tekmal RR; Vadlamudi RK
Cancer Res; 2007 Jun; 67(11):5505-12. PubMed ID: 17545633
[TBL] [Abstract][Full Text] [Related]
13. SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1/2.
Zhang N; Zhang H; Liu Y; Su P; Zhang J; Wang X; Sun M; Chen B; Zhao W; Wang L; Wang H; Moran MS; Haffty BG; Yang Q
Cell Death Differ; 2019 May; 26(5):843-859. PubMed ID: 29988076
[TBL] [Abstract][Full Text] [Related]
14. PELP1: Structure, biological function and clinical significance.
Sareddy GR; Vadlamudi RK
Gene; 2016 Jul; 585(1):128-134. PubMed ID: 26997260
[TBL] [Abstract][Full Text] [Related]
15. MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways.
Li X; Roslan S; Johnstone CN; Wright JA; Bracken CP; Anderson M; Bert AG; Selth LA; Anderson RL; Goodall GJ; Gregory PA; Khew-Goodall Y
Oncogene; 2014 Jul; 33(31):4077-88. PubMed ID: 24037528
[TBL] [Abstract][Full Text] [Related]
16. Downregulated microRNA-200a promotes EMT and tumor growth through the wnt/β-catenin pathway by targeting the E-cadherin repressors ZEB1/ZEB2 in gastric adenocarcinoma.
Cong N; Du P; Zhang A; Shen F; Su J; Pu P; Wang T; Zjang J; Kang C; Zhang Q
Oncol Rep; 2013 Apr; 29(4):1579-87. PubMed ID: 23381389
[TBL] [Abstract][Full Text] [Related]
17. Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells.
Chakravarty D; Nair SS; Santhamma B; Nair BC; Wang L; Bandyopadhyay A; Agyin JK; Brann D; Sun LZ; Yeh IT; Lee FY; Tekmal RR; Kumar R; Vadlamudi RK
Cancer Res; 2010 May; 70(10):4092-101. PubMed ID: 20460518
[TBL] [Abstract][Full Text] [Related]
18. PELP1/MNAR suppression inhibits proliferation and metastasis of endometrial carcinoma cells.
Wan J; Li X
Oncol Rep; 2012 Dec; 28(6):2035-42. PubMed ID: 22992812
[TBL] [Abstract][Full Text] [Related]
19. SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
Liu Z; Liu J; Ebrahimi B; Pratap UP; He Y; Altwegg KA; Tang W; Li X; Lai Z; Chen Y; Shen L; Sareddy GR; Viswanadhapalli S; Tekmal RR; Rao MK; Vadlamudi RK
Breast Cancer Res; 2022 Apr; 24(1):26. PubMed ID: 35395812
[TBL] [Abstract][Full Text] [Related]
20. Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.
Rajhans R; Nair HB; Nair SS; Cortez V; Ikuko K; Kirma NB; Zhou D; Holden AE; Brann DW; Chen S; Tekmal RR; Vadlamudi RK
Mol Endocrinol; 2008 Mar; 22(3):649-64. PubMed ID: 18079323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
